Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.

The companies said they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217.

Consolidation within the industry also remained brisk as cost and reimbursement concerns provided acquisition opportunities for large national outfits.